Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 11-12, 2011, Pages 982-985

  Tsuji, Yasuhiro ^a   Hiraki, Yoichi ^b   Matsumoto, Kana ^c   Mizoguchi, Akiko ^a   Sadoh, Shinichi ^a   Kobayashi, Tsutomu ^a   Takemura, Yusuke ^a   Sakamoto, Seisaburo ^a   Morita, Kunihiko ^c   Kamimura, Hidetoshi ^d   Karube, Yoshiharu ^d  

^a SASEBO CHUO HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^c DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

Bacterial meningitis; Cerebrospinal fluid; Linezolid; Protein binding ratio

Indexed keywords

CEFOZOPRAN; GLUCOSE; LINEZOLID; PROTEIN;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTERIAL MENINGITIS; BACTERIUM CULTURE; BLOOD CELL COUNT; BLOOD PRESSURE; BLOOD SAMPLING; BODY TEMPERATURE; BODY WEIGHT; BRAIN HEMATOMA; CASE REPORT; CEREBROSPINAL FLUID; COMA; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS LEVEL; CRANIOTOMY; DRUG EFFICACY; DYSARTHRIA; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN CELL; HYDROCEPHALUS; HYPOALBUMINEMIA; LETHARGY; LUMBAR PUNCTURE; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RIGIDITY; STAPHYLOCOCCUS EPIDERMIDIS; STOMACH CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CEREBROSPINAL FLUID; HUMANS; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; OXAZOLIDINONES; POSTOPERATIVE COMPLICATIONS; PROTEIN BINDING; PROTEINS; SERUM;

EID: 80755130165     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.600327     Document Type: Article

References (17)

1. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45. (Pubitemid 26117523)
2. Shinabarger DL. Mechanism of action of the oxazolidinone antibacterial agent. Expert Opin Investig Drugs 1999;8: 1195-202.
3. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-62. (Pubitemid 29395210)
4. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratifi cation for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998;129:862-9. (Pubitemid 28549813)
5. Ostabal MI, SuÁ r ez Pinilla MA, Sanz SebastiÁ n C, Millastre A. Epidemiological study of nosocomial meningitis in neurological patients. Rev Neurol 1996;24:265-7.
6. Villani P, Regazzi MB, Marubbi F, Viale P, Pagani L, Cristini F, et al. Cerebrospinal fl uid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46:936-7. (Pubitemid 34157696)
7. Beer R, Engelhardt KW, Pfausler B, Broessner G, Helbok R, Lackner P, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fl uid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007;51:379-82. (Pubitemid 46047736)
8. Majcher-Peszynska J, Haase G, Sass M, Mundkowski R, Pietsch A, Klammt S, et al. Pharmacokinetics and penetration of linezolid into infl amed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64:1093-100.
9. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: Application to lower body weight and elderly patients. J Clin Pharmacol 2009;49:1071-8.
10. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82. (Pubitemid 16050520)
11. Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, Schmutzhard E. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fl uid drains: A prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003;98:1040-4. (Pubitemid 36460895)
12. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129-40. (Pubitemid 37357649)
13. Heinze A, Holzgrabe U. Determination of the extent of protein binding of antibiotics by means of an automated continuou ultrafi ltration method. Int J Pharm 2006;311:108-12.
14. MacGowan AP. Pharmacokinetic and pharmacodynamic profi le of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51 (Suppl 2):ii17 - 25. (Pubitemid 36622108)
15. Slatter JG, Adams LA, Bush EC, Chiba K, Daley-Yates PT, Feenstra KL, et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002;32:907-24. (Pubitemid 35155524)
16. Milhorat TH. The third circulation revisited. J Neurosurg 1975;42:628-45.
17. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001;33:375-9. (Pubitemid 32573988)